Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

Rhabdomyosarcoma (RMS) is a highly metastatic soft-tissue sarcoma that often develops resistance to current therapies, including vincristine. Since the existing treatments have not significantly improved survival, there is a critical need for new therapeutic approaches for RMS patients. FOXM1, a kno...

Full description

Bibliographic Details
Main Authors: Johnny Donovan, Zicheng Deng, Fenghua Bian, Samriddhi Shukla, Jose Gomez-Arroyo, Donglu Shi, Vladimir V. Kalinichenko, Tanya V. Kalin
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
FOXM1 inhibitor
combination therapy
rhabdomyosarcoma
nanoparticles
animal models
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1112859/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1112859/full

Similar Items